![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Adding Baricitinib to COVID-19 Treatment Reduces Mortality by 44 Percent
Adding Baricitinib to COVID-19 Treatment Reduces Mortality by 44 Percent
![Eli lilly logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Lilly_Logo.jpg?t=1616695880&width=430)
August 6, 2021
Mechanically ventilated patients with COVID-19 were 44 percent less likely to die when Olumiant (baricitinib) was added to the standard treatment regimen, according to a substudy of Eli Lilly’s COV-BARRIER trial.
Among the 101 adult patients in the late-stage study, 45 percent of those taking baricitinib died compared to 62 percent of those taking placebo — a 44 percent reduction.
Mortality by day 28 was 46 percent lower, at 29.2 percent in the baricitinib arm and 58 percent in the placebo arm, the company reported.
Upcoming Events
-
21Oct